Ipsen appoints Keira Driansky as EVP, President of North America
May 02 2024 - 12:30AM
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext:
IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical
company, announced today the appointment of Keira Driansky as EVP,
President of North America, effective May 13, 2024. She will serve
on the Executive Leadership Team (ELT) and report directly to
Ipsen’s Chief Executive Officer (CEO), David Loew.
“We are thrilled to welcome Keira to Ipsen as
our new President of North America as she brings extensive
experience in the life sciences industry and a proven track record
of leadership to our team,” said David Loew, CEO Ipsen. “As we
continue to navigate the complexities of the pharmaceutical
landscape, Keira’s strategic vision will be instrumental in guiding
our company toward a future of bringing groundbreaking medicines
and enhanced outcomes to patients.”
Keira will be joining Ipsen from AstraZeneca,
where she spent the last 13 years leading teams across the US,
Europe and global functions. Most recently Keira served as Country
President of AstraZeneca for Belgium and Luxembourg, where she
oversaw 14 launches across various therapeutic areas, leading AZ to
become the fastest-growing pharma company in Belgium. Previously,
she served as VP, Global Commercial Head for Tagrisso across more
than 90 countries. She also spent more than five years in AZ’s US
Oncology business leading multiple sales and marketing teams
through six launches.
A former science researcher, Keira brings broad
experience across the healthcare industry, from commercial
leadership to healthcare investing and business development. She
received her MBA from Harvard Business School and an MPhil in
Bioscience Enterprise from the University of Cambridge. Keira also
conducted breast cancer epidemiology research at the University of
Oxford as a Marshall Scholar and conducted biochemistry research at
Yale under a Howard Hughes Medical Fellowship.
“I’m excited to join the talented and
established team at Ipsen at this time of dynamic growth, with four
innovative launches across therapeutic areas, including the latest
in first-line pancreatic cancer,” said Keira Driansky. “I look
forward to partnering with Ipsen’s employees, customers, and
stakeholders across the healthcare ecosystem to deliver
breakthrough solutions for some of the most pressing global health
challenges of our time."
Stewart Campbell, who as Ipsen’s President of
North America for three years led the acceleration of Ipsen’s
growth, will leave Ipsen to pursue other opportunities.
ENDS
About Ipsen
We are a global biopharmaceutical company with a
focus on bringing transformative medicines to patients in three
therapeutic areas: Oncology, Rare Disease and Neuroscience.
Our pipeline is fueled by external innovation
and supported by nearly 100 years of development experience and
global hubs in the U.S., France and the U.K. Our teams in more than
40 countries and our partnerships around the world enable us to
bring medicines to patients in more than 80 countries.
Ipsen is listed in Paris (Euronext: IPN) and in
the U.S. through a Sponsored Level I American Depositary Receipt
program (ADR: IPSEY). For more information, visit ipsen.com.
Ipsen contacts
Investors
- Craig
Marks | +44 (0)7584 349 193 |
craig.marks@ipsen.com
- Nicolas
Bogler | +33 6 52 19 98 92 |
nicolas.bogler@ipsen.com
Media
- Amy Wolf
| +41 79 576 07 23 |
amy.wolf@ipsen.com
-
Elizabeth Kalina | +1 857 331 0060|
elizabeth.kalina@ipsen.com
Disclaimers and/or Forward-Looking
StatementsThe forward-looking statements, objectives and
targets contained herein are based on Ipsen’s management strategy,
current views and assumptions. Such statements involve known and
unknown risks and uncertainties that may cause actual results,
performance or events to differ materially from those anticipated
herein. All of the above risks could affect Ipsen’s future ability
to achieve its financial targets, which were set assuming
reasonable macroeconomic conditions based on the information
available today. Use of the words ‘believes’, ‘anticipates’ and
‘expects’ and similar expressions are intended to identify
forward-looking statements, including Ipsen’s expectations
regarding future events, including regulatory filings and
determinations. Moreover, the targets described in this document
were prepared without taking into account external-growth
assumptions and potential future acquisitions, which may alter
these parameters. These objectives are based on data and
assumptions regarded as reasonable by Ipsen. These targets depend
on conditions or facts likely to happen in the future, and not
exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain
risks and uncertainties, notably the fact that a promising medicine
in early development phase or clinical trial may end up never being
launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. Ipsen must face or might
face competition from generic medicine that might translate into a
loss of market share. Furthermore, the research and development
process involves several stages each of which involves the
substantial risk that Ipsen may fail to achieve its objectives and
be forced to abandon its efforts with regards to a medicine in
which it has invested significant sums. Therefore, Ipsen cannot be
certain that favorable results obtained during preclinical trials
will be confirmed subsequently during clinical trials, or that the
results of clinical trials will be sufficient to demonstrate the
safe and effective nature of the medicine concerned. There can be
no guarantees a medicine will receive the necessary regulatory
approvals or that the medicine will prove to be commercially
successful. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Other risks
and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact
of pharmaceutical industry regulation and healthcare legislation;
global trends toward healthcare cost containment; technological
advances, new medicine and patents attained by competitors;
challenges inherent in new-medicine development, including
obtaining regulatory approval; Ipsen’s ability to accurately
predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of Ipsen’s patents
and other protections for innovative medicines; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
Ipsen also depends on third parties to develop and market some of
its medicines which could potentially generate substantial
royalties; these partners could behave in such ways which could
cause damage to Ipsen’s activities and financial results. Ipsen
cannot be certain that its partners will fulfil their obligations.
It might be unable to obtain any benefit from those agreements. A
default by any of Ipsen’s partners could generate lower revenues
than expected. Such situations could have a negative impact on
Ipsen’s business, financial position or performance. Ipsen
expressly disclaims any obligation or undertaking to update or
revise any forward-looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such
statements are based, unless so required by applicable law. Ipsen’s
business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des
Marchés Financiers. The risks and uncertainties set out are not
exhaustive and the reader is advised to refer to Ipsen’s latest
Universal Registration Document, available on ipsen.com.
- Ipsen PR_Keira Driansky_02052024
Ipsen (EU:IPN)
Historical Stock Chart
From May 2024 to Jun 2024
Ipsen (EU:IPN)
Historical Stock Chart
From Jun 2023 to Jun 2024